Chromadex Corp

NASDAQ:CDXC   10:23:01 AM EDT
8.72
-0.27 (-3.00%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)592.39M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$17.16 Million
Adjusted EPS-$0.08
See more estimates
10-Day MA$9.37
50-Day MA$8.49
200-Day MA$6.83
See more pivots

Chromadex Corp Stock, NASDAQ:CDXC

10900 Wilshire Boulevard, Suite 600, Los Angeles, California 90024
United States of America
Phone: +1.310.388.6706
Number of Employees: 110

Description

Chromadex Corp. is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The companyâ??s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services. The Consumer Products segment provides finished dietary supplement products that contain the firmâ??s proprietary ingredients directly to consumers as well as to distributors. The Ingredients segment supplies ingredients as raw materials to the manufacturers of consumer products. The Analytical Reference Standards and Services segment includes supply of phytochemical reference standards and other research and development services. The company was founded by Mark S. Germain and Frank L. Jaksch, Jr. in 1999 and is headquartered in Los Angeles, CA.